DRW Securities’s Takeda Pharmaceutical TAK Stock Holding History

DRW Securities’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,416	Closed	-$153K	–	1689
2025 Q3	$153K	Buy	+10,416	New	+$155K	﹤0.01%	1130

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DRW Securities's TAK Position: Q4 2025 in Review

DRW Securities sold out of Takeda Pharmaceutical (TAK) in Q4 2025, closing a stake of 10,416 shares — an estimated $153K sold.

DRW Securities first reported a position in TAK in Q3 2025 and held it in 1 quarter. The position peaked at $153K in Q3 2025. 348 funds tracked by Wall St. Rank hold TAK as of Q4 2025.

DRW Securities reported no remaining Takeda Pharmaceutical position as of Q4 2025 after selling out during the quarter.
DRW Securities sold 10,416 Takeda Pharmaceutical shares in Q4 2025, an estimated $153K.
DRW Securities first reported a position in Takeda Pharmaceutical in Q3 2025 and held it in 1 quarter.
DRW Securities's Takeda Pharmaceutical position peaked at $153K in Q3 2025.
348 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2025.

Based on DRW Securities's 13F filing for Q4 2025, filed 12 Feb 2026.